Kornimate/medical-research-clean huggingface dataset:
efficacy study of oral sapacitabine to treat acute myeloid leukemia in elderly patients

Conditions: Acute Myeloid Leukemia

Summary: the objective is to treat elderly aml and mds patients with sapacitabine.

the main objective of this study is to learn which sapacitabine treatment is more likely to keep the cancer in check for at least one year in aml patients who are at least 70 years of age or older and in mds patients who are at least 60 years of age.

Eligibility criteria:
inclusion criteria: * a histologically or pathologically confirmed diagnosis of aml based on who classification which is previously untreated by systemic therapy or is in first relapse after achieving a complete remission to initial induction, consolidation and/or maintenance therapy or mds with ipss scores of intermediate -2 or higher risk risk which has been previously treated with hypomethylating agents * age 70 years or older for aml and 60 years or older for mds * eastern cooperative oncology group (ecog) performance status 0-2 * adequate renal function defined as serum creatinine equal to or less than 1.5 x upper limit of normal (uln) * adequate liver function defined as total bilirubin or direct bilirubin equal to or less than 1.5 x uln; alanine aminotransferase (alt or sgpt) equal to or less than 2.5 x uln (5 x uln if tumor has affected the liver) * life expectancy reasonably adequate for evaluating the treatment effect * patient must be able to swallow capsules * patients must be at least 2 weeks from prior systemic therapy, radiation therapy, major surgery, or other investigational therapy, and have recovered from clinically significant toxicities of these prior treatments * all men and women of reproductive potential must agree to practice effective contraception for 4 weeks prior to study entry, during the entire study period and for one month after the study unless documentation of infertility exists * ability to understand and willingness to sign the informed consent form exclusion criteria: * aml is of the sub-type of acute promyelocytic leukemia * having received more than one induction systemic therapy for aml or having received a standard dose or high dose ara-c containing regimen for mds * patients with known central nervous system (cns) involvement by leukemia * uncontrolled intercurrent illness including, but not limited to ongoing or active infection, active cancer(s) other than aml, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. patients receiving intravenous antibiotics for infections that are under control may be included in this study * known to be hiv-positive
a study on impact of canagliflozin on health status, quality of life, and functional status in heart failure

Conditions: Heart Failure

Summary: the purpose of this study is to determine the superiority of the effectiveness of canagliflozin 100 milligram (mg) daily versus placebo in participants with symptomatic heart failure (hf) in improving the overall kansas city cardiomyopathy questionnaire (kccq) total symptom score (tss).


Eligibility criteria:
inclusion criteria: - have clinically stable symptomatic heart failure (hf) (heart failure with reduced ejection fraction \[hfref\] and heart failure with preserved ejection fraction \[hfpef\]): (a) for hfref: (a) ejection fraction (ef) less than or equal to (\ ) 40%; (b) a primary diagnosis of hf or 2 medical visits (including virtual) with a hf diagnosis code in any position in the past 18 months, and; (c) on a loop diuretic or spironolactone or eplerenone (mineralocorticoid receptor antagonists), in the past 18 months * have a baseline kansas city cardiomyopathy questionnaire (kccq) score of less than or equal to (\<=) 80 prior to randomization * be able to read and understand english * possess and have sole use (example: not shared with other users) of smartphone compatible with the fitbit device * willing/able to wear the fitbit device on a regular basis for the 9-month study period exclusion criteria: * currently taking a sodium-glucose co-transporter 2 inhibitor (sglt2i) or within the last 3 months * history of diabetic ketoacidosis or have type 1 diabetes mellitus (t1dm) * have acute decompensated hf (exacerbation of symptomatic hf) requiring intravenous diuretics, inotropes, or vasodilators within the last 4 weeks * have stage 4 or 5 chronic kidney disease (that is, estimated glomerular filtration rate \[egfr\] \<30 milliliter per minute \[ml/min\] on dialysis) from the most recent assessment * have a diagnosis of hypotension within 30 days
study to assess iron chelation therapy in patients with chronic iron overload

Conditions: Chronic Iron Overload

Summary: this is a prospective, multicenter, non-interventional study. findings are analyzed using epidemiological methods.

this nis shall document the therapy of chronic iron overload in a broad patient population with either of the approved iron chelators in germany. the choice of patients and the therapy according to the smpc follows the clinical routine exclusively. the regular observation time per patient is 24 months. corresponding to the clinical routine, follow up visits can be documented after approximately 1, 3, 6, 9, 12 and 18 month with a close out visit after 24 month. in case the iron chelator is switched, the visit scheme should be passed through once again.

Eligibility criteria:
inclusion criteria: male and female adult patients suffering from chronic iron overload * who never received an iron chelator directly before starting an iron chelation therapy * who received an iron chelation therapy for less than 6 month * who interrupted an iron chelation therapy for longer than 6 months and will receive an iron chelation therapy again * who signed the informed consent exclusion criteria: -

Keywords: chronic iron overload germany nis
comparison of balloon sinuplasty in-office versus medical management for recurrent acute sinusitis patients (cabernet)

Conditions: Recurrent Acute Rhinosinusitis

Summary: this post-market study aims to compare health outcomes for recurrent acute rhinosinusitis (rars) patients treated with balloon sinus dilation (bsd) versus medical management alone.


Eligibility criteria:
inclusion criteria: * 19 years of age or greater * diagnosis of recurrent acute rhinosinusitis * suitable candidate for office-based procedure * willing and able to read and sign informed consent and remain compliant with protocol and study procedures * able to read and understand english exclusion criteria: * diagnosis of chronic rhinosinusitis * prior sinus surgery * physician determined need for ancillary procedures * known immune deficiency, ciliary dysfunction and/or autoimmune disease * clinically significant illness that may interfere with evaluation of the study * participation in clinical studies 6 months prior to study participation * pregnant or lactating females
delayed antibiotic treatment in community-acquired pneumococcal pneumonia.

Conditions: Community-acquired Pneumonia

Summary: i. to investigate time measurement from emergency room admission to first antibiotic administration. ii. to evaluate risk factors for prolonged time to first antibiotic administration. iii. to correlate time measurement with charlson comorbidity index and multimorbidity patterns. iv. to investigate the impact of a delayed time to first antibiotic administration on the outcome

in this retrospective cohort study, we plan to include all patients presenting with a community-acquired pneumococcal pneumonia at the university hospital of zurich between january 1, 2006 and june 30, 2012 (6½ years). the patients will be identified either with one or more blood culture pairs positive for s. pneumoniae or with a positive pneumococcal urine antigen assay in combination with the clinical diagnosis of cap, which was based on the presence of select clinical features (e.g., cough, fever, sputum production, and pleuritic chest pain) and is supported by imaging of the lung, usually by chest radiography according to infectious diseases society of america/american thoracic society consensus guidelines on the management of cap in adults \[11\]. cap is not considered if the patient is discharged from a hospital less than 7 days before the current hospital admission, if the first blood culture or urinary antigen assay is obtained more than 1 week after hospital admission, or if the patient has no clinical diagnosis of cap at the time of admission. patients referred from or transferred to another hospital are excluded. after identification of eligible patients upon microbiological results, medical records are reviewed using a standardized data collection questionnaire. comorbidity is determined using the charlson comorbidity index \[10\]. additionally, all patients are classified according to the multimorbidity patterns proposed by holden et al. \[12\]. these are: 1. arthritis, osteoporosis, other chronic pain, bladder problems, and irritable bowel; 2. asthma, chronic obstructive pulmonary disease, and allergies; 3. back/neck pain, migraine, other chronic pain, and arthritis; 4. high blood pressure, high cholesterol, obesity, diabetes, and fatigue; 5. cardiovascular disease, diabetes, fatigue, high blood pressure, high cholesterol, and arthritis; and 6. irritable bowel, ulcer, heartburn, and other chronic pain. time calculation is based upon the moment of emergency room (er) admission.

Eligibility criteria:
inclusion criteria: patients with community-acquired pneumococcal pneumonia, which was confirmed by 1. detection of streptococcus pneumoniae in blood cultures, tracheal secretion or sputum or/and 2. positive urinary pneumococcal antigen and 3. presence of cough and presence of one of the following signs/symptoms: new focal chest signs; dyspnoea; tachypnoea; fever and 4. radiologic signs of pneumonia exclusion criteria: - pneumonia of other cause (e.g. non-pneumococcal pneumonia) * hospital-acquired or ventilator-associated pneumonia * patients referred from or transferred to another hospital
thin and ultrathin bronchoscopy with transbronchial needle aspiration and radial probe endobronchial ultrasound for peripheral pulmonary lesions

Conditions: Peripheral Pulmonary Nodules

Summary: to collect data on diagnostic yield of thin and ultrathin bronchoscopes with radial probe endobronchial ultrasound (radial ebus) and transbronchial needle aspiration (tbna) during routine standard of care bronchoscopy for peripheral pulmonary lesions.


Eligibility criteria:
inclusion criteria: * patients age 18 and older * patients presenting with peripheral pulmonary lesions 1-7cm in greatest diameter on axial ct or pet scan in need of bronchoscopic biopsy for clinical purposes exclusion criteria: * patients who are unable to undergo flexible bronchoscopy as determined by the bronchoscopist prior to the procedure * patients unwilling or unable to provide informed consent.
temperature response to a head-neck cooling system

Conditions: Healthy

Summary: this study will evaluate the effectiveness of a specially designed head-neck cooling system for way lowering the body's central, or core, temperature and cooling the brain. brain cooling has an effect on stopping seizure discharges in the brain as well as the seizures themselves. if this system works to cool the brain, a similar study may be tried in patients with epilepsy. normal volunteers 21 years of age and older who have no medical or neurological condition and do not use any medications may be eligible for this study. candidates will be screened with an interview. women will have a pregnancy test. those enrolled will be hospitalized twice for overnight stays, with the admissions 2 to 3 days apart. participants will have a medical history, physical and neurological examinations, electroencephalogram (eeg) and electrocardiogram (ekg). then, electrodes will be attached to their scalp, forearm and calf to measure temperatures in those locations. intestinal (core) temperature will be measured with a temperature-sensing pill, which will be swallowed earlier), and a hand-held infrared thermometer will be used to measure temperatures from the ear canal, face, head, arms legs, and abdomen. electrodes on the scalp will also measure changes in blood volume in the brain for a study of brain blood flow. subjects will be seated in a comfortable chair and fitted with the cooling system, a portable unit with a circulating coolant. cooling will last 30 minutes for the first session and 60 minutes for the second. participants will be monitored for at least 30 minutes after each session to track temperature changes and have a post-cooling eeg recording.

the aim of this protocol is to study thermal responses in normal volunteers using a special cooling system designed to cool the head and neck. temperature will be monitored at various locations including the scalp, face, mouth, ears (tympanic), arms, legs, and rectum. previous studies indicate that cooling of the brain can be achieved with the head-neck cooling method. we hope to derive cooling parameters that will be used in a future study involving patients with epilepsy.

Eligibility criteria:
inclusion criteria: 21 years and older no neurological or medical condition no use medication of any kind, including prescription, over-the-counter or herbal medicines. no history of any kind of gastrointestinal tract disorders exclusion criteria: women who are pregnant (screened with urine pregnancy test) those with progressive neurological disorders those sensitive to coldness those taking medication those who smoke those whose heart rate less than 50 or more than 100 those who are less than 80 pounds or excessively overweight those who have a history of gastrointestinal disorders (i.e. diverticulitis and other inflammatory bowel diseases) those who have difficulty swallowing or whose gag reflex is impaired

Keywords: brain temperature lower tympanic rectal cooling of the head and neck control epilepsy healthy volunteer hv
cross-over comparison of gabapentin and memantine as treatment for acquired nystagmus

Conditions: Nystagmus

Summary: involuntary oscillations of the eyes (nystagmus) impairs vision so that affected patients, who have neurological disorders such as multiple sclerosis (ms) , cannot read or watch tv. two medicines have been reported to suppress nystagmus and improve vision in such patients: gabapentin and memantine. the investigators set out to test which of these two drug was more effective by carrying out a double-blind cross-over study. in this way, we could determine which drug worked best in each patient.

the study entails careful measurements of visual acuity and precise measurements of eye movements, using a contact lens device (magnetic search coil method). in this way, it is possible to make objective and reliable measurements of the effect of each drug, which are unbiased by the investigator or the patient.

Eligibility criteria:
inclusion criteria: * adult (18 years or older) males or females with acquired nystagmus that is degrading their vision exclusion criteria: * pregnant women * individuals who cannot describe their visual symptoms, cooperate with testing, or give informed consent * individuals with intolerance of gabapentin or memantine

Keywords: gabapentin memantine nystagmus drug treatment
better hips- better function

Conditions: Hip Fracture

Summary: the focus of this project are elderly people who have experienced hip fracture and need at least two weeks rehabilitation after discharge from hospital. the aim is to increase the evidence-based knowledge base for planning and appropriate follow-up intervention for patients with hip fracture on short-term / rehabilitation stays. in this study the investigators want to explore whether training high intensity functional exercises (hife) , of short duration ie a 2- 4 week program and frequent intervention ie 5 times per week has a significant positive effect on physical function, pain and quality of life. the main aim is to explore whether a high intensive strength and balance training program has better effect than a low intensive strength and balance training program on functional status measured by short physical performance battery (sppb) in patients with hip fractures. another aims is to explore whether this high intensive strength and balance training program has better effect than a 'low intensive strength and balance training program' on pain, endurance and quality of life measured respectively numeric pain rating scale (npr), 6-minute walk test and sf-36. the study is a randomized controlled trial.


Eligibility criteria:
inclusion criteria: * fractura colli femoris, pertrochantar or subtrochantar) * discharged from hospital within 3 weeks since surgery. * need of minimum two weeks rehabilitation * life expectancy of more than one month * able to walk at least 3 m with walking aid * willingness to participate * able to follow instructions * 65 years or older exclusion criteria: -other reasons for gait impairment than hip fracture

Keywords: physiotherapy hip fracture rehabilitation high dose exercise low dose exercise
application and revision of montreal cognitive assessment in chinese retirees

Conditions: Mild Cognitive Impairment

Summary: the study was designed to employ moca to screen mild cognitive impairment (mci) in military retirees and to analyze the associated risk factors. as such, moca was revised to be validated for the chinese context.

three hundred and four retired military cadres were investigated using a random cluster sampling technique including personal information, prevalence, moca scale, and related neuropsychiatry scale. thirty retirees were random chosen and tested again with the revised moca scale one month later.

Eligibility criteria:
inclusion criteria: * aged \>=60 years old retired military cadres lived in xian,shaanxi,china questionnaires completed exclusion criteria: * deaf-mute
hiv/cov in ukraine-nl

Conditions: Hiv; Covid19

Summary: contradicting preliminary results are available on the impact of covid-19 in people with hiv (pwh). how achieving goals of the hiv 90-90-90 cascade of care influences the risk of covid-19 in pwh is unclear. the primary objective is to determine the impact of covid-19 in pwh cohorts from ukraine and the netherlands.


Eligibility criteria:
inclusion criteria: hiv infected no registered objection to use of data exclusion criteria: none
bern venous stent registry

Conditions: Post-thrombotic Syndrome

Summary: the purpose of this study is to examine patency rates of self-expanding nitinol stents for treatment of iliofemoral and inferior vena cava residual thrombosis, obstruction or stenosis. moreover, clinical outcome data of patients treated with these venous stents will be collected.

background: obstruction and stenosis of the ilio-femoro-caval veins are difficult to treat by conservative measures only. despite anticoagulation and consequent use of compression stockings, lower extremity venous hypertension affects patients quality of life and health status by causing venous claudication, swelling, skin changes, and venous ulcers. in the last decades venous stenting has become an accepted treatment for ilio-femoro-caval obstruction. recently, novel self-expanding nitinol stents have been specifically designed for the venous system to account for the anatomical structure of ilio-femoro-caval veins. gap of knowledge: there are few data on short and long term outcomes of self-expanding nitinol stent placement in ilio-femoro-caval veins. objective: to study patency rates and clinical outcome data of self-expanding nitinol stents that were specifically designed for iliofemoral and inferior vena cava residual thrombosis, obstruction or stenosis.

Eligibility criteria:
inclusion criteria: patients receiving self-expanding venous nitinol stents for one of the following indications: * residual thrombosis of iliofemoral veins and/or inferior vena cava after thrombus removal (by catheter-directed thrombolysis or pharmacomechanical thrombolysis) * post-thrombotic syndrome and chronic obstruction of iliofemoral veins and/or inferior vena cava * chronic venous insufficiency and presence of non-thrombotic venous stenosis of iliofemoral veins and/or inferior vena cava exclusion criteria: * no consent * inability to provide informed consent * allergy to nitinol * pregnancy, breast-feeding or birth-giving during the last 30 days * life expectancy \<3 months

Keywords: deep vein thrombosis chronic venous disease may-thurner syndrome venous stent
effect of sour liquid on swallowing function of the patients with stroke

Conditions: Acute Stroke

Summary: the aim of this study was to evaluate the effect of early administration of sour liquid on swallowing function of patients with post-stroke dysphagia. hypothesis of the study were; h0: the sour liquid given early to patients with post-stroke dysphagia does not have an effect on swallowing function h1: the sour liquid given early to patients with post-stroke dysphagia has an effect on swallowing function the data of the study were collected using the "personal information form," "standard swallowing test," "gagging swallowing screening test (guss)," and the " national institute of health stroke scale (nihss)". early administration of sour liquid to patients with post-stroke dysphagia was found to have a positive effect on swallowing function.

background: untreated and undetected swallowing disorders lead to increased morbidity and mortality in acute stroke patients due to inadequate nutrition, dehydration, and aspiration pneumonia leading to prolonged hospital stays, decreased functionality, and increased long-term care needs. the aim of this study was to evaluate the effect of early administration of sour liquid on swallowing function of patients with post-stroke dysphagia. materials and methods: this study was a randomized controlled trial, which was conducted with 95 patients with confirmed diagnosis of ischemic stroke and dysphagia, admitted to the neurology department of a university hospital. the intervention group (n=47) received 4 ml of room temperature lemon juice, while the control group (n=48) received 4 ml of room temperature water before breakfast, lunch, and dinner for a duration of 7 days. the standard swallowing test, gagging swallowing screen, and national institutes of health stroke scale were applied. swallowing function and stroke severity were assessed at initial assessment, at the end of the 7th and 30th days.

Eligibility criteria:
inclusion criteria: * diagnosed with ischemic stroke, * had not completed the first 72 hours after diagnosis, * developed swallowing disorders, * volunteered to participate in the study exclusion criteria: * diagnosed hemorrhagic stroke, * had completed the first 72 hours after diagnosis, * not developed swallowing disorders, * not volunteered to participate in the study

Keywords: acute stroke dysphagia swallowing function sour taste
comparison of different up-dosing schedules with osiris

Conditions: Allergic Rhinitis

Summary: the purpose of this study is to compare different up-dosing schedules with osiris.


Eligibility criteria:
inclusion criteria: * history of grass pollen allergy * positive spt to grass * positive ige to grass exclusion criteria: * uncontrolled and severe asthma

Keywords: rhinitis allergic immunotherapy